ANPCF
CelLBxHealth plc
Price Chart
Latest Quote
$0.02
+0.00 (+0.00%)
Current Price
| Previous Close | $0.02 |
| Open | $0.01 |
| Day High | $0.01 |
| Day Low | $0.01 |
| Volume | 20,000 |
Stock Information
Note: Financial values converted from GBP to USD
| Shares Outstanding | 1.95B |
| Total Debt | $4.93M |
| Cash Equivalents | $7.08M |
| Revenue | $3.53M |
| Net Income | $-21.20M |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Market Cap | $38.74M |
| EPS (TTM) | $-0.06 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $4.82M |
| Sales | $3.53M |
| Income | $-21.20M |
| Book/sh | $0.05 |
| Cash/sh | $0.00 |
| Employees | 119 |
Financial Ratios
| Quick Ratio | 2.63 |
| Current Ratio | 3.13 |
| Debt/Eq | 31.35 |
Returns & Margins
| ROA | -39.98% |
| ROE | -87.18% |
| Gross Margin | 31.36% |
| Operating Margin | -1215.70% |
Ownership
| Insider Ownership | 5.69% |
| Institutional Ownership | 31.71% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 14.77 |
| P/B | 0.41 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.01 |
| SMA50 | $0.01 |
| SMA200 | $0.03 |
| RSI | 100.00 |
| ATR | 0.0007 |
| Shares Float | 140.52M |
| Volatility | 0.21 |
Performance History
| Week | +0.00% |
| Month | +93.20% |
| Quarter | +45.15% |
| 6 Months | +18.45% |
| YTD | +18.45% |
| Year | -87.64% |
| 3 Years | -96.17% |
| 5 Years | -98.18% |
| 10 Years | -98.30% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-03 | $0.02 | 0 |
| 2026-06-02 | $0.02 | 0 |
| 2026-06-01 | $0.02 | 0 |
| 2026-05-29 | $0.02 | 0 |
| 2026-05-28 | $0.02 | 0 |
| 2026-05-27 | $0.02 | 0 |
| 2026-05-26 | $0.02 | 0 |
| 2026-05-22 | $0.02 | 0 |
| 2026-05-21 | $0.02 | 260 |
| 2026-05-20 | $0.01 | 0 |
| 2026-05-19 | $0.01 | 0 |
| 2026-05-18 | $0.01 | 0 |
| 2026-05-15 | $0.01 | 0 |
| 2026-05-14 | $0.01 | 0 |
| 2026-05-13 | $0.01 | 0 |
| 2026-05-12 | $0.01 | 0 |
| 2026-05-11 | $0.01 | 0 |
| 2026-05-08 | $0.01 | 0 |
| 2026-05-07 | $0.01 | 0 |
| 2026-05-06 | $0.01 | 0 |
| 2026-05-05 | $0.01 | 0 |
| 2026-05-04 | $0.01 | 0 |
About CelLBxHealth plc
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company also has a research collaboration with The Royal Marsden NHS Foundation Trust. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
đ° Latest News
CelLBxHealth Insider Confidence Rewarded, Stock Hits UKÂŖ24m Market Cap
Simply Wall St. âĸ 2026-05-31T07:33:24Z
Ariana Resources, CelLBxHealth, Tooru, Sintana Energy, 88 Energy, Powerhouse Energy
Proactive âĸ 2026-05-18T09:03:08Z
CelLBxHealth, Caledonia Mining, Rome Resources, EGT, IBT, Pantheon International
Proactive âĸ 2026-05-15T11:34:48Z
CelLBxHealth targets growth after ÂŖ6.6m cost-cutting overhaul
Proactive âĸ 2026-05-11T14:10:52Z
CelLBxHealth, Poolbeg Pharma, Caledonia Mining, Empire Metals, 88 Energy, Atlantic Lithium
Proactive âĸ 2026-05-11T08:27:16Z
CelLBxHealth, Genflow, Active Energy, Caledonia Mining, Great Southern Copper, Rome Resources
Proactive âĸ 2026-04-20T09:36:25Z
CelLBxHealth shares rise 3% as company continues to focus on cost base
Proactive âĸ 2026-02-13T09:15:06Z
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
Proactive âĸ 2026-02-13T07:17:00Z
Jan Groen Spends UKÂŖ50k On CelLBxHealth Stock
Simply Wall St. âĸ 2025-12-22T05:02:10Z
CellBxHealthâs new CEO pivots strategy amid financial turnaround efforts
Medical Device Network âĸ 2025-12-19T18:26:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,083,000 | $658,000 | $428,000 | $302,000 |
| Cost Of Revenue | $1,083,000 | $658,000 | $428,000 | $302,000 |
| Total Revenue | $2,862,000 | $2,186,000 | $1,041,000 | $1,013,000 |
| Operating Revenue | $2,862,000 | $2,186,000 | $1,041,000 | $1,013,000 |
| Expenses | ||||
| Interest Expense | $307,000 | $325,000 | $354,000 | $157,000 |
| Total Expenses | $18,336,000 | $22,644,000 | $27,150,000 | $18,340,000 |
| Rent Expense Supplemental | $2,000 | $27,000 | $34,000 | $61,000 |
| Net Non Operating Interest Income Expense | $89,000 | $138,000 | $-218,000 | $-128,000 |
| Interest Expense Non Operating | $307,000 | $325,000 | $354,000 | $157,000 |
| Operating Expense | $17,253,000 | $21,986,000 | $26,722,000 | $18,038,000 |
| Other Operating Expenses | $4,194,000 | $5,873,000 | $5,257,000 | $2,862,000 |
| General And Administrative Expense | $455,000 | $382,000 | $557,000 | $342,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Net Interest Income | $89,000 | $138,000 | $-218,000 | $-128,000 |
| Interest Income | $396,000 | $463,000 | $136,000 | $29,000 |
| Normalized Income | $-14,214,588 | $-20,053,825 | $-21,533,375 | $-14,990,385 |
| Net Income From Continuing And Discontinued Operation | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Total Operating Income As Reported | $-15,096,000 | $-21,759,000 | $-24,207,000 | $-17,235,000 |
| Net Income Common Stockholders | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Net Income | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Net Income Including Noncontrolling Interests | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Net Income Continuous Operations | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Pretax Income | $-15,029,000 | $-21,632,000 | $-24,439,000 | $-17,363,000 |
| Special Income Charges | $-11,000 | $-84,000 | $-172,000 | $-25,000 |
| Interest Income Non Operating | $396,000 | $463,000 | $136,000 | $29,000 |
| Operating Income | $-15,474,000 | $-20,458,000 | $-26,109,000 | $-17,327,000 |
| Depreciation And Amortization In Income Statement | $1,698,000 | $2,308,000 | $2,838,000 | $1,466,000 |
| Depreciation Income Statement | $1,564,000 | $2,240,000 | $1,860,000 | $1,233,000 |
| Gross Profit | $1,779,000 | $1,528,000 | $613,000 | $711,000 |
| Per Share | ||||
| Diluted EPS | $-0.05 | $-0.08 | $-0.09 | $-0.07 |
| Basic EPS | $-0.05 | $-0.08 | $-0.09 | $-0.07 |
| Other | ||||
| Tax Effect Of Unusual Items | $-588 | $-5,825 | $-19,375 | $-3,385 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-13,013,000 | $-18,915,000 | $-21,075,000 | $-15,694,000 |
| Total Unusual Items | $-11,000 | $-84,000 | $-172,000 | $-25,000 |
| Total Unusual Items Excluding Goodwill | $-11,000 | $-84,000 | $-172,000 | $-25,000 |
| Reconciled Depreciation | $1,698,000 | $2,308,000 | $2,838,000 | $1,487,000 |
| EBITDA (Bullshit earnings) | $-13,024,000 | $-18,999,000 | $-21,247,000 | $-15,719,000 |
| EBIT | $-14,722,000 | $-21,307,000 | $-24,085,000 | $-17,206,000 |
| Diluted Average Shares | $294,932,245 | $260,888,075 | $246,977,995 | $225,436,988 |
| Basic Average Shares | $294,932,245 | $260,888,075 | $246,977,995 | $225,436,988 |
| Diluted NI Availto Com Stockholders | $-14,225,000 | $-20,132,000 | $-21,686,000 | $-15,012,000 |
| Otherunder Preferred Stock Dividend | $0 | $0 | $0 | $0 |
| Tax Provision | $-804,000 | $-1,500,000 | $-2,753,000 | $-2,351,000 |
| Other Special Charges | $11,000 | $84,000 | $172,000 | $4,000 |
| Amortization | $134,000 | $68,000 | $978,000 | $233,000 |
| Research And Development | $1,768,000 | $2,476,000 | $4,039,000 | $3,441,000 |
| Selling General And Administration | $455,000 | $382,000 | $557,000 | $342,000 |
| Rent And Landing Fees | $2,000 | $27,000 | $34,000 | $61,000 |
| Impairment Of Capital Assets | - | - | $787,000 | $21,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $15,793,000 | $20,198,000 | $37,299,000 | $36,757,000 |
| Total Assets | $25,458,000 | $31,183,000 | $49,868,000 | $47,315,000 |
| Total Non Current Assets | $9,050,000 | $9,967,000 | $11,240,000 | $7,949,000 |
| Goodwill And Other Intangible Assets | $2,648,000 | $2,741,000 | $2,764,000 | $3,573,000 |
| Other Intangible Assets | $441,000 | $534,000 | $557,000 | $1,366,000 |
| Current Assets | $16,408,000 | $21,216,000 | $38,628,000 | $39,366,000 |
| Inventory | $1,579,000 | $1,679,000 | $2,059,000 | $1,748,000 |
| Other Receivables | $1,024,000 | $750,000 | $1,453,000 | $1,012,000 |
| Taxes Receivable | $2,606,000 | $1,842,000 | $2,876,000 | $4,510,000 |
| Accounts Receivable | $774,000 | $727,000 | $317,000 | $202,000 |
| Cash Cash Equivalents And Short Term Investments | $10,425,000 | $16,218,000 | $31,896,000 | $31,839,000 |
| Cash And Cash Equivalents | $10,425,000 | $16,218,000 | $31,896,000 | $31,839,000 |
| Debt | ||||
| Total Debt | $4,210,000 | $4,554,000 | $5,001,000 | $2,338,000 |
| Long Term Debt And Capital Lease Obligation | $3,348,000 | $3,905,000 | $4,339,000 | $1,816,000 |
| Current Debt And Capital Lease Obligation | $862,000 | $649,000 | $662,000 | $522,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $7,017,000 | $8,244,000 | $9,805,000 | $6,985,000 |
| Total Non Current Liabilities Net Minority Interest | $3,759,000 | $4,301,000 | $4,555,000 | $2,073,000 |
| Tradeand Other Payables Non Current | $49,000 | $26,000 | $59,000 | $257,000 |
| Current Liabilities | $3,258,000 | $3,943,000 | $5,250,000 | $4,912,000 |
| Payables | $1,075,000 | $1,421,000 | $2,204,000 | $2,169,000 |
| Other Payable | $32,000 | $51,000 | $51,000 | $35,000 |
| Total Tax Payable | $348,000 | $311,000 | $658,000 | $1,010,000 |
| Accounts Payable | $695,000 | $1,059,000 | $1,495,000 | $1,124,000 |
| Equity | ||||
| Common Stock Equity | $18,441,000 | $22,939,000 | $40,063,000 | $40,330,000 |
| Total Equity Gross Minority Interest | $18,441,000 | $22,939,000 | $40,063,000 | $40,330,000 |
| Stockholders Equity | $18,441,000 | $22,939,000 | $40,063,000 | $40,330,000 |
| Other Equity Interest | $3,652,000 | $5,607,000 | $5,219,000 | $2,625,000 |
| Retained Earnings | $-133,145,000 | $-122,328,000 | $-103,702,000 | $-83,808,000 |
| Other | ||||
| Treasury Shares Number | $113,259 | $0 | - | - |
| Ordinary Shares Number | $322,528,409 | $261,001,517 | $261,001,517 | $235,522,925 |
| Share Issued | $322,641,668 | $261,001,517 | $261,001,517 | $235,522,925 |
| Tangible Book Value | $15,793,000 | $20,198,000 | $37,299,000 | $36,757,000 |
| Invested Capital | $18,441,000 | $22,939,000 | $40,063,000 | $40,330,000 |
| Working Capital | $13,150,000 | $17,273,000 | $33,378,000 | $34,454,000 |
| Capital Lease Obligations | $4,210,000 | $4,554,000 | $5,001,000 | $2,338,000 |
| Total Capitalization | $18,441,000 | $22,939,000 | $40,063,000 | $40,330,000 |
| Additional Paid In Capital | $118,362,000 | $115,918,000 | $115,918,000 | $99,406,000 |
| Capital Stock | $32,264,000 | $26,058,000 | $26,058,000 | $23,514,000 |
| Common Stock | $32,264,000 | $26,058,000 | $26,058,000 | $23,514,000 |
| Long Term Capital Lease Obligation | $3,348,000 | $3,905,000 | $4,339,000 | $1,816,000 |
| Long Term Provisions | $362,000 | $370,000 | $157,000 | - |
| Current Capital Lease Obligation | $862,000 | $649,000 | $662,000 | $522,000 |
| Current Provisions | $179,000 | $544,000 | $610,000 | - |
| Goodwill | $2,207,000 | $2,207,000 | $2,207,000 | $2,207,000 |
| Net PPE | $6,402,000 | $7,226,000 | $8,476,000 | $4,376,000 |
| Accumulated Depreciation | $-4,536,000 | $-4,162,000 | $-3,354,000 | $-2,889,000 |
| Gross PPE | $10,938,000 | $11,388,000 | $11,830,000 | $7,265,000 |
| Other Properties | $5,011,000 | $4,949,000 | $9,383,000 | $3,766,000 |
| Machinery Furniture Equipment | $462,000 | $475,000 | $522,000 | $413,000 |
| Buildings And Improvements | $5,465,000 | $5,964,000 | $1,925,000 | $3,086,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $1,579,000 | $1,453,000 | $1,892,000 | $986,000 |
| Raw Materials | $0 | $226,000 | $167,000 | $762,000 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-13,892,000 | $-15,118,000 | $-17,937,000 | $-15,798,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-13,448,000 | $-14,458,000 | $-16,050,000 | $-14,010,000 |
| Investing Activities | ||||
| Capital Expenditure | $-444,000 | $-660,000 | $-1,887,000 | $-1,788,000 |
| Investing Cash Flow | $-48,000 | $-201,000 | $-1,751,000 | $14,774,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $8,631,000 | $14,000 | $19,045,000 | $19,690,000 |
| Financing Cash Flow | $7,668,000 | $-1,127,000 | $18,096,000 | $18,991,000 |
| Net Common Stock Issuance | $8,631,000 | $14,000 | $19,045,000 | $19,690,000 |
| Common Stock Issuance | $8,631,000 | $14,000 | $19,045,000 | $19,690,000 |
| Net Other Financing Charges | - | $2,000 | - | - |
| Other | ||||
| End Cash Position | $10,425,000 | $16,218,000 | $31,896,000 | $31,839,000 |
| Beginning Cash Position | $16,218,000 | $31,896,000 | $31,839,000 | $12,080,000 |
| Effect Of Exchange Rate Changes | $35,000 | $108,000 | $-238,000 | $4,000 |
| Changes In Cash | $-5,828,000 | $-15,786,000 | $295,000 | $19,755,000 |
| Interest Paid Cff | $-158,000 | $-182,000 | $-135,000 | $-85,000 |
| Interest Received Cfi | $396,000 | $457,000 | $136,000 | $24,000 |
| Net Intangibles Purchase And Sale | $-33,000 | $-49,000 | $-169,000 | $-122,000 |
| Purchase Of Intangibles | $-33,000 | $-49,000 | $-169,000 | $-122,000 |
| Net PPE Purchase And Sale | $-411,000 | $-609,000 | $-1,718,000 | $-1,666,000 |
| Sale Of PPE | $0 | $2,000 | - | - |
| Purchase Of PPE | $-411,000 | $-611,000 | $-1,718,000 | $-1,666,000 |
| Taxes Refund Paid | $0 | $2,863,000 | $4,447,000 | $-27,000 |
| Change In Working Capital | $-1,132,000 | $-1,031,000 | $-1,614,000 | $606,000 |
| Change In Payable | $-585,000 | $-1,011,000 | $-978,000 | $1,417,000 |
| Change In Inventory | $153,000 | $90,000 | $-580,000 | $-1,015,000 |
| Change In Receivables | $-304,000 | $-74,000 | $-650,000 | $204,000 |
| Other Non Cash Items | $-67,000 | $-127,000 | $232,000 | $128,000 |
| Stock Based Compensation | $1,453,000 | $1,894,000 | $4,386,000 | $1,325,000 |
| Depreciation And Amortization | $1,698,000 | $2,308,000 | $2,838,000 | $1,487,000 |
| Amortization Cash Flow | $134,000 | $68,000 | $978,000 | $254,000 |
| Depreciation | $1,564,000 | $2,240,000 | $1,860,000 | $1,233,000 |
| Net Foreign Currency Exchange Gain Loss | $-382,000 | $1,183,000 | $-2,072,000 | $-170,000 |
| Gain Loss On Sale Of PPE | $11,000 | $84,000 | $172,000 | $4,000 |
| Net Income From Continuing Operations | $-15,029,000 | $-21,632,000 | $-24,439,000 | $-17,363,000 |
| Net Investment Purchase And Sale | - | - | $0 | $16,538,000 |
Fetched: 2026-02-02